J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it
A little more than three years ago, J&J stepped up with a $12.5 million upfront to rent a front row seat on Capricor Therapeutics’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
